Psoriasis

Psoriasis – Epidemiology – Americas

DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well…

Psoriasis – Epidemiology – Mature Markets

DRG Epidemiology's coverage of psoriasis (PsO) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the total symptomatic prevalence of PsO…

Psoriasis – Epidemiology – Emerging Markets

DRG Epidemiology's coverage of psoriasis comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the prevalence of PsO for each country, as well…

Psoriasis | Unmet Need | US/EU | 2018

IL-17 inhibitors have set a new efficacy standard in moderate to severe psoriasis, putting pressure on the more established TNF-α inhibitors and the IL-12/23 inhibitor Stelara. Although IL-17…

Psoriasis | Unmet Need | US/EU | 2017

IL -17 inhibitors have established a high standard for efficacy in moderate to severe psoriasis, placing pressure on current therapies that are less efficacious and a great number of…